While the development of isoform-selective HDAC-specific inhibitors are still in progress, many lines of evidence including experimental and clinical studies attest a promising effect for the use of HDACi as epigenetic drugs in cancer treatment; nevertheless, several obstacles related to solid malignancies have been encountered [302,303,304]. This evidence concerns the gene HDAC9 and cancer.